Literature DB >> 11597668

Direct-to-consumer advertisements for prescription drugs: what are Americans being sold?

S Woloshin1, L M Schwartz, J Tremmel, H G Welch.   

Abstract

BACKGROUND: Pharmaceutical companies spent US$1.8 billion on direct-to-consumer advertisements for prescription drugs in 1999. Our aim was to establish what messages are being communicated to the public by these advertisements.
METHODS: We investigated the content of advertisements, which appeared in ten magazines in the USA. We examined seven issues of each of these published between July, 1998, and July, 1999.
FINDINGS: 67 advertisements appeared a total of 211 times during our study. Of these, 133 (63%) were for drugs to ameliorate symptoms, 54 (26%) to treat disease, and 23 (11%) to prevent illness. In the 67 unique advertisements, promotional techniques used included emotional appeals (45, 67%) and encouragement of consumers to consider medical causes for their experiences (26, 39%). More advertisements described the benefit of medication with vague, qualitative terms (58, 87%), than with data (9, 13%). However, half the advertisements used data to describe side-effects, typically with lists of side-effects that generally occurred infrequently. None mentioned cost.
INTERPRETATION: Provision of complete information about the benefit of prescription drugs in advertisements would serve the interests of physicians and the public.

Mesh:

Substances:

Year:  2001        PMID: 11597668     DOI: 10.1016/S0140-6736(01)06254-7

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  32 in total

1.  Direct-to-consumer prescription drug advertising in Canada: permission by default?

Authors:  David M Gardner; Barbara Mintzes; Aleck Ostry
Journal:  CMAJ       Date:  2003-09-02       Impact factor: 8.262

2.  Visual presentations of efficacy data in direct-to-consumer prescription drug print and television advertisements: A randomized study.

Authors:  Helen W Sullivan; Amie C O'Donoghue; Kathryn J Aikin; Dhuly Chowdhury; Rebecca R Moultrie; Douglas J Rupert
Journal:  Patient Educ Couns       Date:  2015-12-22

3.  Randomized study of placebo and framing information in direct-to-consumer print advertisements for prescription drugs.

Authors:  Amie C O'Donoghue; Helen W Sullivan; Kathryn J Aikin
Journal:  Ann Behav Med       Date:  2014-12

4.  Creating demand for prescription drugs: a content analysis of television direct-to-consumer advertising.

Authors:  Dominick L Frosch; Patrick M Krueger; Robert C Hornik; Peter F Cronholm; Frances K Barg
Journal:  Ann Fam Med       Date:  2007 Jan-Feb       Impact factor: 5.166

Review 5.  Direct-to-consumer advertising of pharmaceuticals: developed countries experiences and Turkey.

Authors:  Semih Semin; Sahbal Aras; Dilek Guldal
Journal:  Health Expect       Date:  2007-03       Impact factor: 3.377

6.  Time to ban direct-to-consumer prescription drug marketing.

Authors:  Kurt C Stange
Journal:  Ann Fam Med       Date:  2007 Mar-Apr       Impact factor: 5.166

Review 7.  Cost of pharmacological care of the elderly: implications for healthcare resources.

Authors:  Ciaran O'Neill; Carmel M Hughes; James Jamison; Anna Schweizer
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

8.  Learning from marketing: Rapid development of medication messages that engage patients.

Authors:  Veronica Yank; Erika Tribett; Lydia Green; Jasmine Pettis
Journal:  Patient Educ Couns       Date:  2015-03-14

9.  Factors affecting physicians' responses to patients' requests for antidepressants: focus group study.

Authors:  Aleksey Tentler; Jordan Silberman; Debora A Paterniti; Richard L Kravitz; Ronald M Epstein
Journal:  J Gen Intern Med       Date:  2007-11-07       Impact factor: 5.128

10.  Direct-to-consumer and physician promotion of tegaserod correlated with physician visits, diagnoses, and prescriptions.

Authors:  Spencer D Dorn; Joel F Farley; Richard A Hansen; Nilay D Shah; Robert S Sandler
Journal:  Gastroenterology       Date:  2009-05-13       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.